{"id":93419,"date":"2026-06-27T23:49:21","date_gmt":"2026-06-27T23:49:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/93419\/"},"modified":"2026-06-27T23:49:21","modified_gmt":"2026-06-27T23:49:21","slug":"roche-boosts-us-presence-with-new-700-million-north-carolina-facility","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/93419\/","title":{"rendered":"Roche boosts US presence with new $700 million North Carolina facility"},"content":{"rendered":"

May 12 (Reuters) – Roche Group (ROG.S), opens new tab<\/a> said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump’s tariff policies.<\/p>\n

The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech’s future portfolio of next-generation obesity medicines.<\/p>\n

Sign up here.<\/a><\/p>\n

Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.<\/p>\n

Roche acquired rights to petrelintide, an obesity therapy from Denmark’s Zealand Pharma (ZELA.CO), opens new tab<\/a> in March. This therapy is currently undergoing mid-stage clinical trials.<\/p>\n

Roche’s obesity pipeline also includes experimental obesity and diabetes drugs from its acquisition of Carmot Therapeutics in 2023.<\/p>\n

“This initial investment could expand in the future, based on business needs and the U.S. policy environment,” the company said in a statement.<\/p>\n

Roche in April said<\/a> it would invest $50 billion in the United States over the next five years, with plans to create more than 12,000 new jobs.This announcement is part of a broader trend of massive investments by drugmakers such as Eli Lilly (LLY.N), opens new tab<\/a>, Johnson & Johnson (JNJ.N), opens new tab<\/a> and Gilead (GILD.O), opens new tab<\/a> that have also recently pledged additional investments to boost domestic production in response to President Trump’s tariff policies.<\/p>\n

The Trump administration has been pressuring U.S. drugmakers to relocate production domestically. Last week, President Trump signed an executive order to expedite pharmaceutical plant approvals, encouraging U.S.-based manufacturing.<\/p>\n

Trump also said he plans to sign<\/a> an executive order on prescription drug pricing on Monday that aims to align the United States with what other countries pay, a move he said on social media could result in a 59% reduction in drug prices.<\/p>\n

Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber<\/p>\n

Our Standards: The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n

Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"May 12 (Reuters) – Roche Group (ROG.S), opens new tab said on Monday that it plans to invest…\n","protected":false},"author":2,"featured_media":93420,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[18218,15510,26126,46750,4967,31466,46751,15523,15524,15513,18227,46742,31467,31486,15530,45174,31485,15528,15529,18220,32316,46746,2082,10873,15525,26132,46752,2228,18215,15515,46753,26134,26135,46754,3738,1245,31470,15476,46755,31471,31472,46756,18219,32317,46747,46743,15517,46744,15518,15519,21532,21533,15521,46748,31484,134,32314,18230,31465,18224,46745,15526,714,21534,10872,46749],"class_list":["post-93419","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-amers","tag-bact","tag-bisv","tag-bisv08","tag-biz","tag-bmat","tag-bmat08","tag-ceeu","tag-ch","tag-cmpny","tag-cprod","tag-dbt","tag-deal1","tag-destlita","tag-destocabsm","tag-destohlt","tag-destoma","tag-destoukbsm","tag-destousbsm","tag-destoushem","tag-dk","tag-drugen","tag-emea","tag-europ","tag-fin","tag-fins","tag-fins08","tag-gen","tag-hea","tag-heca","tag-humdis","tag-invbis","tag-invm","tag-invs08","tag-job","tag-legal","tag-min","tag-mine","tag-mine08","tag-mrg","tag-mtal","tag-mtal08","tag-namer","tag-nord","tag-obesit","tag-phag08","tag-phar","tag-phar08","tag-phar1","tag-phmr","tag-pol","tag-potus","tag-publ","tag-pve","tag-reuters-legal","tag-roche","tag-scandv","tag-topcmb","tag-topicmarkets-commodities-metals","tag-topicpharma-healthcare-business-health","tag-topicpharma-healthcare-healthcare-innovation","tag-topnws","tag-us","tag-wash","tag-weu","tag-xpand"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=93419"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93419\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/93420"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=93419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=93419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=93419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}